丝裂原活化蛋白激酶（ERK）信号通路：用于治疗BRAF基因变异的转移性黑色素瘤的研究性联合疗法
The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.
作者信息
McCain Jack
出版信息
P T. 2013 Feb;38(2):96-108.
Abstract
The arrival of ipilimumab and vemurafenib has provided oncologists with new choices in a field in which options were slim and the prognosis was grim. Combination therapy may lead to an improved survival benefit.
摘要
伊匹单抗和维莫非尼的出现为肿瘤学家们在一个选择有限且预后严峻的领域提供了新的选择。联合治疗可能会带来更好的生存获益。
相似文献
1
2
Ipilimumab and vemurafenib: two different routes for targeting melanoma.依匹单抗和威罗菲尼：针对黑色素瘤的两种不同途径。
Curr Cancer Drug Targets. 2013 Oct;13(8):879-94. doi: 10.2174/15680096113139990080.
3
Current and future roles of targeted therapy and immunotherapy in advanced melanoma.靶向治疗和免疫疗法在晚期黑色素瘤中的当前和未来作用。
J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. doi: 10.18553/jmcp.2014.20.4.346.
4
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.阿替利珠单抗、考比替尼和维莫非尼作为不可切除的转移性BRAF V600突变黑色素瘤的一线治疗方案。
Expert Rev Anticancer Ther. 2022 Jan;22(1):17-25. doi: 10.1080/14737140.2022.2017286. Epub 2022 Jan 2.
5
Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.在日常生活环境中，使用现代治疗药物（威罗菲尼和易普利姆玛）治疗转移性黑色素瘤的长期生存。
Med Oncol. 2018 Jan 31;35(3):24. doi: 10.1007/s12032-018-1084-9.
6
Vemurafenib.维莫非尼
Recent Results Cancer Res. 2014;201:215-25. doi: 10.1007/978-3-642-54490-3_13.
7
Multiplying therapies and reducing toxicity in metastatic melanoma.转移性黑色素瘤的联合治疗与毒性降低
Cancer Biol Ther. 2015;16(7):1014-8. doi: 10.1080/15384047.2015.1046650. Epub 2015 May 27.
8
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.一种新型水溶性丝裂原活化蛋白激酶（MAPK）激活剂在对BRAF抑制剂威罗菲尼耐药的黑色素瘤细胞中发挥抗肿瘤活性。
Biochem Pharmacol. 2015 May 1;95(1):16-27. doi: 10.1016/j.bcp.2015.03.004. Epub 2015 Mar 17.
9
Vemurafenib.维莫非尼
Recent Results Cancer Res. 2018;211:77-89. doi: 10.1007/978-3-319-91442-8_6.
10
Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.维莫非尼：针对突变 BRAF 的靶向抑制治疗晚期黑色素瘤及其在其他恶性肿瘤中的潜力。
Drugs. 2012 Dec 3;72(17):2207-22. doi: 10.2165/11640870-000000000-00000.
引用本文的文献
1
Regulatory roles of circular RNAs in Wnt and other oncogenic signaling pathways in breast cancer progression: a comprehensive review.环状RNA在乳腺癌进展中Wnt及其他致癌信号通路中的调控作用：综述
Eur J Med Res. 2025 Aug 14;30(1):750. doi: 10.1186/s40001-025-02967-9.
2
α-Mangostin Is a Xanthone Derivative from Mangosteen with Potent Immunomodulatory and Anti-Inflammatory Properties.α-山竹黄酮是一种来自山竹的氧杂蒽酮衍生物，具有强大的免疫调节和抗炎特性。
Biomolecules. 2025 May 7;15(5):681. doi: 10.3390/biom15050681.
3
PFOS and Its Substitute OBS Cause Endothelial Dysfunction to Promote Atherogenesis in ApoE Mice.全氟辛烷磺酸及其替代物全氟辛基磺酸辛酯引发内皮功能障碍，促进载脂蛋白E基因敲除小鼠的动脉粥样硬化形成。
Environ Health (Wash). 2025 Feb 11;3(5):526-538. doi: 10.1021/envhealth.4c00206. eCollection 2025 May 16.
4
Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.小分子B-RAF抑制剂作为抗癌治疗药物：发现、开发及机制研究进展
Int J Mol Sci. 2025 Mar 16;26(6):2676. doi: 10.3390/ijms26062676.
5
The Correlation Between Biological Markers and Prognosis in Thyroid Cancer.甲状腺癌生物学标志物与预后的相关性
Biomedicines. 2024 Dec 12;12(12):2826. doi: 10.3390/biomedicines12122826.
6
[Molecular basis of ameloblastoma pathogenesis: A review].[成釉细胞瘤发病机制的分子基础：综述]
Rev Cient Odontol (Lima). 2024 Sep 17;12(3):e212. doi: 10.21142/2523-2754-1203-2024-212. eCollection 2024 Jul-Sep.
7
Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization.巨噬细胞膜伪装仿生纳米颗粒通过调节巨噬细胞极化治疗类风湿关节炎。
J Nanobiotechnology. 2024 Sep 19;22(1):578. doi: 10.1186/s12951-024-02822-9.
8
Case report: Metastatic -mutated adult Wilms' tumor with robust response to inhibitor therapy.病例报告：转移性 - 突变型成人肾母细胞瘤对 抑制剂治疗反应良好。 （你原文中部分内容缺失，这里是按照完整翻译思路呈现的，补充完整的话比如“转移性NTRK1基因融合突变型成人肾母细胞瘤对TRK抑制剂治疗反应良好” ）
Front Oncol. 2024 Jul 15;14:1376270. doi: 10.3389/fonc.2024.1376270. eCollection 2024.
9
Multimodal Mass Spectrometry Imaging of an Osteosarcoma Multicellular Tumour Spheroid Model to Investigate Drug-Induced Response.用于研究药物诱导反应的骨肉瘤多细胞肿瘤球体模型的多模态质谱成像
Metabolites. 2024 May 29;14(6):315. doi: 10.3390/metabo14060315.
10
Exportin 1 governs the immunosuppressive functions of myeloid-derived suppressor cells in tumors through ERK1/2 nuclear export.外排蛋白 1 通过 ERK1/2 核输出来调控肿瘤中髓源性抑制细胞的免疫抑制功能。
Cell Mol Immunol. 2024 Aug;21(8):873-891. doi: 10.1038/s41423-024-01187-1. Epub 2024 Jun 20.
本文引用的文献
1
2
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.广泛存在生长因子驱动的抗癌症激酶抑制剂耐药性的潜力。
Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249.
3
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.肿瘤微环境通过分泌 HGF 引发对 RAF 抑制剂的先天抵抗。
Nature. 2012 Jul 26;487(7408):500-4. doi: 10.1038/nature11183.
4
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.达拉非尼治疗 BRAF 突变型转移性黑色素瘤：一项多中心、开放标签、III 期随机对照临床试验。
Lancet. 2012 Jul 28;380(9839):358-65. doi: 10.1016/S0140-6736(12)60868-X. Epub 2012 Jun 25.
5
Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.黑色素瘤化疗导致 ABCB5 表达细胞的选择。
PLoS One. 2012;7(5):e36762. doi: 10.1371/journal.pone.0036762. Epub 2012 May 24.
6
Improved survival with MEK inhibition in BRAF-mutated melanoma.MEK 抑制对 BRAF 突变型黑色素瘤的生存改善。
N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.
7
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.BRAF 抑制剂和伊匹单抗在转移性黑色素瘤患者中的测序：一种可能的临床应用算法。
J Transl Med. 2012 May 28;10:107. doi: 10.1186/1479-5876-10-107.
8
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".黑色素瘤研究的未来展望。“黑色素瘤研究：从那不勒斯到世界的桥梁。那不勒斯，2011 年 12 月 5 日-6 日”会议报告。
J Transl Med. 2012 Jul 4;10:83. doi: 10.1186/1479-5876-10-83.
9
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.BRAF、MEK 和 PI3K/mTOR 抑制剂的联合应用克服了由 NRAS 或 MEK 突变介导的 BRAF 抑制剂 GSK2118436（dabrafenib）获得性耐药。
Mol Cancer Ther. 2012 Apr;11(4):909-20. doi: 10.1158/1535-7163.MCT-11-0989. Epub 2012 Mar 2.
10
Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas.克服黑色素瘤中B-RAF抑制剂耐药性的联合疗法。
Pharmacogenomics. 2012 Jan;13(2):125-8. doi: 10.2217/pgs.11.166.
Zotero 插件